Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths

Traws Pharma Inc. on Friday announced plans to push ahead with possible clinical candidates targeting hantavirus infections, shifting the antiviral developer’s focus after a lethal outbreak on a cruise ship. The company hasn’t disclosed a frontrunner. Chief Scientific Officer C. David Pauza said Traws “plans to rapidly advance clinical candidates.” Chief Medical Officer Robert R. Redfield described the move as an emergency push for “life-saving treatments.”